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Magnolia officinalis has been widely used in traditional Chinese medicine. Magnolol, an active component isolated
from Magnolia officinalis, is known to be a cardiovascular protector since 1994. The multiplex mechanisms of
magnolol on cardiovascular protection depends on cell types and dosages, and will be reviewed and discussed in
this article. Magnolol under low and moderate dosage possesses the ability to protect heart from ischemic/
reperfusion injury, reduces atherosclerotic change, protects endothelial cell against apoptosis and inhibits
neutrophil-endothelial adhesion. The moderate to high concentration of magnolol mainly acts on smooth muscle
cells and platelets. Magnolol induces apoptosis in vascular smooth muscle cells at moderate concentration and
inhibits proliferation at moderate and high concentration. High concentration of magnolol also abrogates platelet
activation, aggregation and thrombus formation. Magnolol also serves as an smooth muscle relaxant only upon the
high concentration. Oral intake of magnolol to reach the therapeutic level for cardiovascular protection is
applicable, thus makes magnolol an agent of great potential for preventing cardiovascular diseases in high-risk
patients.
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Magnolol is an active component isolated from Magno-
lia officinalis (Magnolia bark). Magnolia officinalis is a
traditional Chinese medicine widely used in facilitating
bowel movement and ameliorate abdominal fullness.
The bark is stripped from the stems, branches, and roots
of Magnolia tree, and which is highly aromatic and poly-
phenolic components containing magnolol and honokiol
(Figure 1) [1,2]. In addition to purification of magnolol
from Magnolia-bark, preparation of synthetic magnolol/
honokiol, its analogues and derivatives has been well
established [3-6]. In the past decades, magnolol has been
characterized as an anti-oxidant , anti-depressant, anti-
allergic, anti-cancer and anti-microbial agent [7-11].
Using isolated rat heart mitochondria as an ex vivo
model, Hong et al. demonstrated that magnolol exhibited
free radical scavenging activities shown by the diphenyl-p-
picrylhydrazyl assay, which was less potent than alpha-* Correspondence: hongprof@tmu.edu.tw
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reproduction in any medium, provided the ortocopherol (vitamin E) [12]. However, the ability of inhi-
biting ADP- or ferrous sulfate-induced heart mitochon-
drial lipid peroxidation from magnolol was 1000 times
higher than which from alpha-tocopherol [12]. The lipid
peroxidation inhibition ability by magnolol was not only
found in isolated heart mitochondria, but also shown in
preventing or treating rat from cecal ligation-induced sep-
sis by a dose-dependent manner from 10-6 to 10-2 mg/kg
of magnolol via intravenous injection [13].
The potent antioxidant activities of magnolol and hono-
kiol are thought to be the contribution of hydroxyl and al-
lylic groups on a biphenolic moiety. The hydroxyl group
on biphenolic moiety results in magnolol/honokiol against
reactive oxygen species, inhibiting cell proliferation and
antimicrobial activity [3,6,14]. It has been reported that
most of allylated biphenolic magnolol/honokiol analogues
possessed anti-proliferative activity and anti-MRSA cap-
acity while magnolol analogues with flexible allylated
biphenolic structure showed a better anti-virus activity
than simple allylated ones [4,5]. In addition, the derivatives
of honokiol with the biaryl structure bearing a hydroxyl
and a allyl groups at the 4'-hydroxyl shown to be essential
for neurite outgrowth-promoting activity [15].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
BA




Molecular Formula: C18H18O2 





Figure 1 Structure and chemical characteristics of magnolol and honokiol. Magnolol (A) and honokiol (B) are isomers extracted from
Magnolia officinalis. Both of magnolol and honokiol are lipophilic, biphenoid structure with molecular weight of 226.334. The melting point of
magnolol is higher than that of honokiol.
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type specific effect. In this article, we will focus on tissues/
cells involved in cardiovascular diseases, i.e. cardiomyo-
cytes, endothelial cells, neutrophils, macrophages, platelets
and smooth muscle cells in coronary artery and aorta. Lit-
eratures of magnolol research on cardiovascular protec-
tion, including our efforts, in the past 20 years will be
reviewed and summarized in this article.
Effects and molecular mechanisms of magnolol on
cardiovascular system
The cardiovascular protection potentiality of magnolol
through its antioxidant activity is first demonstrated by
Hong et al. in 1994 [12]. It is well known that free radi-
cals attack lipid membrane, protein and DNA. Excessive
free radicals induce lipid peroxidation, protein denature
and DNA damage, and that triggers cell death. In
addition, vascular stenosis, cell death and inflammation
are the major progressive factors to worse the cardiac
function as well as vascular complications during cardio-
vascular dysfunction. In the past 20 years, magnolol has
been found to have diverse functions in different cells of
cardiovascular system. Those effects are dose-related,
and are the consequence of different molecular mechan-
isms regulated by magnolol.
Magnolol protects heart from myocardial infarction and
ischemia/reperfusion injury
Magnolol reduces ventricular arrhythmia
In a series of animal studies, Hong and his team members
demonstrated that intravenous injection of magnolol at thedosage above 10-6 mg/kg before coronary artery ligation
successfully inhibited both ischemia- and reperfusion-
induced ventricular tachycardia and ventricular fibrillation,
while 10-5 mg/kg of magnolol and above significantly
reduced the infarct size [16]. Honokiol had been found to
more efficient for reducing ligation-induced infarct size
(>10-6 mg/kg) but less sensitive to ventricular arrhythmia
inhibition (at the dosage of 10-4 mg/kg) than magnolol [17].
Furthermore, to explore the mechanism of ventricular
arrhythmia inhibition by magnolol, pretreatment of nitric
oxide inhibitor (L-NAME) or cyclooxygenase inhibitor (as-
pirin) before ligation demonstrated that nitric oxide synthe-
sis may also be involved in the anti-arrhythmic effect of
magnolol or honokiol (10-7 mg/kg) [18].
Magnolol inhibits neutrophil infiltration in myocardium and
restores systolic wall thickening fraction
Magnolol protected rabbit myocardium against coronary
artery ligation-induced stunning evidenced by signifi-
cantly enhancing the recovery of systolic wall thickening
fraction 60 minutes after coronary artery reperfusion at
the dosage from 10-4 to 10-3 mg/kg, relatively higher
than which of reducing ventricular arrhythmia [19].
Under such concentration (2–5 x 10-4 mg/kg), magnolol
could also prevent rat myocardium from ischemia/
reperfusion injury and neutrophil infiltration [20].
Magnolol promotes coronary vasodilatation and inhibits
myocardium apoptosis
Magnolol has been reported to possess the ability of redu-
cing coronary arterial resistance after ligation under a high
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cular resistance using pulsed Doppler velocimetry [21], sug-
gesting that the underlying mechanism of magnolol
responsible for coronary vasodilatation and myocardium
protection is independent. Except for coronary vasodilata-
tion, high concentration of magnolol at 10 mg/kg via intra-
peritoneal injection also demonstrated the ability to prevent
myocardial ischemia and reperfusion injury associated car-
diomyocytes apoptosis through enhancing the activation of
ERK1/2 and modulation of the Bcl-xl proteins [22]. How-
ever, the regulation of ERK1/2 signaling pathway by magno-
lol shows a reciprocal effect in cardiomyocyte and
cardiofibroblast. For rat cardiac fibroblast, on the contrary,
magnolol (10 μM) significantly inhibited urotensin-II-
induced proliferation through inhibiting ERK1/2 activation
and interfering with ROS generation [23]. The in vitro
results from cardiac fibroblasts indicate that magnolol may
have a potential to decrease cardiac fibrotic change during
the regenerative stage after infarction.
Magnolol prevents atherosclerosis and vessel restenosis
Magnolol attenuates postangioplastic restenosis
Hyperlipidemia, resulting in atherosclerotic change, is
one of the major risk factors for myocardial infarction
and postangioplastic restenosis. In 2001, using balloon
injury in a hyperlipidemic rabbit, Chen et al. demon-
strated that daily intramuscular injection of 10-3 mg/kg
magnolol for 6 weeks attenuated intimal thickening and
MCP-1 expression induced by balloon denudation. Such
effect of magnolol was related to inhibition of LDL oxi-
dation rather than decreasing plasma lipid level [24],
showing that lipid peroxidation inhibition by magnolol
plays a role to prevent vessel restenosis.
Magnolol induces apoptosis and inhibits proliferation in
vascular smooth muscle cells
Although ox-LDL contributes to vessel stenosis, intimal
thickening is a direct consequence of vascular smooth
cells proliferation. In experimental studies, magnolol was
found to inhibit intimal hyperplasia induced by high-
cholesterol diet [24]. Next, several research groups work
on investigating the direct effect of magnolol on vascular
smooth muscle cells instead of LDL peroxidation.
Magnolol (5 to 20 μM) per se dose-dependently
induced apoptosis in vascular smooth muscle cells by in-
creasing DNA fragmentation and activating caspase-3
and −9 activities. Magnolol reduced mitochondrial
membrane potential which was Bcl-2 dependent [25].
However, under serum or TNFα stimulation, vascular
smooth muscle cell proliferation can be abrogated by
magnolol. Wu et al. reported that magnolol at the con-
centration of 50 μg/ml (200 μM) significantly reduced
vascular smooth muscle cells progressing to the S-phase
when DNA synthesis was triggered by serum. Theproliferation inhibition by magnolol was also associated
with reducing malondialdehyde formation, downregula-
tion of NF-κB and increasing caspase-3 [26], suggesting
that the proliferation inhibition may a net result from
G1 cell cycle arrest, anti-oxidation and apoptosis induc-
tion by magnolol. Indeed, in the following research by
Kim's group, 5 to 20 μM of magnolol concentration-
dependently inhibited TNFα-induced vascular smooth
cell proliferation through reducing ERK1/2 activity. In-
hibition of ERK1/2 activity led to G1 cell cycle arrest
which was a consequence of p21 upregulation and sub-
sequent decrease in CDK-2 and CDK-4. Hence, magno-
lol also decreased MMP-9 promoter activity in vascular
smooth muscle cells in response to TNFα, and which
was transcriptional regulated by NF-κB and AP-1 [27].
Magnolol promotes vessel dilation
In addition to affect on smooth muscle cell numbers,
magnolol also works as a smooth muscle relaxant. In
1975, magnolol was found to act as a centrally acting
muscle relaxant [28], such an effect was referred to mag-
nolol with two hydroxyls into 2- and 2'-position of
diphenyl molecule [29]. In 1990, Teng et al. found that
high concentration as 10–100 μg/ml (40–400 μM) of
magnolol efficiently blocked norepinephrine- or high K
+-induced contraction of rat aorta in the present of
endothelium [30]. Since that time, endothelium-derived
relaxing factor and voltage-gated Ca2+ channels are
thought to be the targets of magnolol in releasing
smooth muscle tone. Further studies reported that both
magnolol and honokiol at the concentration from 0.1 to
100 μM irreversibly abrogated carbachol- and high K
+-induced smooth muscle contractions in porcine tra-
chea and rat uterine without affecting the basal muscle
tension. The mechanism of smooth muscle tone inhib-
ition by magnolol directed to the blockade of Ca2+ influx
through voltage-operated Ca2+ channels instead of Ca2+
release from intracellular Ca2+ stores [31,32].
Magnolol inhibits vascular endothelial cell death
Magnolol shows reciprocal regulation on ERK1/2 activity
in cardiomyocyte and fibroblast. Alternatively, magnolol
inhibits the activation of NF-κB signaling pathway
resulting in different effects on vascular smooth muscle
cells, endothelial cells and neutrophils.
For vascular smooth muscle cells, magnolol induces
cell death via activation of intrinsic (mitochondrial)
apoptosis; however, for vascular endothelial cells, mag-
nolol protects the cell viability through inhibition of in-
trinsic apoptosis. Using copper-induced ox-LDL to
trigger intrinsic apoptosis, magnolol (2.5 to 20 μM)
showed the protective effect on vascular endothelial cells
via removal of intracellular ROS, so that ROS-induced
cytochrome c releasing, caspase-3 activation as well as
Figure 2 Schema of magnolol in cardiovascular protection. Magnolol protects heart from ischemic/reperfusion heart injury, reduces
atherosclerotic change and endothelial cell apoptosis, inhibits neutrophil activation/adhesion and vascular smooth muscle cell proliferation,
prevents platelet aggregation and thrombosis, and promotes vessel relaxation under different dosages.
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to magnolol, protect vascular endothelial cells against
apoptosis. In an in vitro model of hyperglycemia-
induced endothelial damage, honokiol (0.125 to 1 μM)
suppressed NF-κB regulated COX-2 upregulation and
intrinsic apoptosis [34]. Although it has been demon-
strated that magnolol protects endothelial cells from
the ox-LDL-induced apoptosis, the endothelial protec-
tion with magnolol per se is still unclear so far.
Magnolol inhibits acute inflammation
Magnolol inhibits macrophage activation and suppresses
neutrophil aggregation, activation and migration
In LPS-activated macrophage, both magnolol and honkiol
inhibited iNOS expression and TNFα releasing. However,
honokiol (IC50 6.4 μM) showed stronger inhibition effect
on macrophage than magnolol (IC50 16.8 μM) [35].
During acute cardiovascular injury, neutrophil aggrega-
tion, activation, migration, endothelial adhesion and infil-
tration initiate a series of inflammatory responses which
worse the cardiovascular function. Magnolol (30–90 μM)
per se induced cytosolic-free Ca2+ elevation in neutrophil
by stimulating Ca2+ release from internal stores and Ca2+
influx across the plasma membrane via activating inositoltrisphosphate signalling pathway [36]. Upon PMA stimu-
lation, magnolol at low concentration (0.1-10 μM) dose-
dependently diminished PMA-induced Mac-1 (CD11b/
CD18) upregulation in neutrophil and reduced sequential
adhesion ability. Such effect was similar to exogenous
superoxide dismutase or catalase showing that magnolol
served as an anti-oxidant in abrogating neutrophil adhe-
sion [37]. Furthermore, in vivo study demonstrated that
magnolol suppressed cytosolic PKC activity in [3 H]phor-
bol 12,13-dibutyrate-labeled neutrophil rather than rat
brain PKC activity with an IC 50 of 24.2± 1.7 μM. The at-
tenuation of PKC activity in neutrophil by magnolol was
responsible for its inhibition of neutrophil aggregation
[38]. Hence, magnolol at 5–50 μM showed significantly
suppress fMLP-activated human neutrophil migration in a
concentration-dependent manner [20]. The above findings
support that magnolol directly regulates neutrophil in an
inflammatory environment.
Magnolol reduces neutrophil-endothelial adhesion
The next issue should be answered is whether magnolol
can block the neutrophil-endothelial adhesion. For vascu-
lar endothelial cells, suppression of NF-κB regulated sig-
nals by magnolol leaded to anti-apoptotic effect [33,34]. It
Table 1 Summary of in vivo magnolol effect on cardiovascular system
Dosage Effect Reference
Low (10-7~10-4 mg/kg)
10-7~−6 mg/kg (i.v.) Prevent post MI-induced ventricular arrythmia [16,18]
10-5 mg/kg (i.v.) Decrease MI-induced infarct size [16]
Moderate (10-4~10-2 mg/kg)
10-4~−3 mg/kg (i.v.) Protect myocardium against MI-induced myocardial wall thinning [19]
2-5 × 10-4 mg/kg (i.v.) Decrease neutrophil infiltration in infarct heart [20]
10-3 mg/kg (i.m.) daily Attenuate balloon-induced intimal thickening and inhibit LDL oxidation [24]
10-3 mg/kg (i.m.) daily Attenuate hypercholesteremia-induced intimal thickening, TNFα and VCAM-1 elevation in an aorta. [40]
High (≧10-1 mg/kg)
10-1 mg/kg (i.v.) Reduce coronary artery resistance after MI [21]
10 mg/kg (i.p.) Prevent MI-induced cardiomyocyte apoptosis [22]
i.v.: intravenous injection; i.m.: intramuscular injection; i.p.: intraperitoneal injection.
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in vascular endothelial cells also results in both pro-
inflammatory cytokines/chemokines releasing and cell
adhesion molecules expression such as VACM-1, ICAM-
1 and endothelial cell selectin [39], that promotes
neutrophil-endothelial adhesion. In 2002, Chen et al.
demonstrated that magnolol (5 and 10 μM) selectively
inhibited TNFα-induced VACM-1 expression by abrogat-
ing nuclear translocation of NF-kB p65 in human aortic
endothelial cells. They further confirmed that in vivo mag-
nolol (10-3 mg/kg daily via intramuscular injection) atte-
nuated the intimal thickening, TNFα and VCAM-1
protein expression in the thoracic aortas of cholesterol-fedTable 2 Summary of in vitro magnolol effect on cardiovascula
Concentration Eff
Low (≦1 μM) to Moderate
0.1-10 μM Diminish PMA-induced neutrophil activation and reduce ne
Moderate (1–100 μM)
5-10 μM Inhibited TNFα-induced VACM-1 expression in aortic endoth
10 μM Inhibit proliferation of cardiac fibroblasts
16.8 μM Inhibit LPS-induced macrophage activation
5-20 μM Induce intrinsic apoptosis in vascular smooth muscle cells
5-20 μM Inhibit TNFα-induced vascular smooth muscle cell proliferat
>20 μM Downregulate IL-6-induced ICAM-1 expression in endotheli
2.5-20 μM Inhibit copper-induced ox-LDL triggered endothelial cell ap
24.2 μM Inhibit neutrophil aggregation
3-30 μM Inhibit collagen-induced platelet serotonin release
5-50 μM Suppress fMLP-activated neutrophil migration
30-90 μM induce cytosolic-free Ca2+ elevation in neutrophil
Moderate to High (≧100 μM)
200 μM Reduce serum-induced vascular smooth muscle cell prolifer
40-400 μM block norepinephrine- or high K+−induced contraction of a
60-150 μM Inhibit biosynthesis of platelet-activating factor from PMNsrabbits [40]. Besides, magnolol at the concentration above
20 μM completely abolished IL-6-induced STAT3 phos-
phorylation in bovine aortic endothelial cells, and further
downregulated ICAM-1, cyclin D1 and MCP-1 expression.
The downregulation of ICAM-1 by magnolol resulted in
suppression of IL-6-induced monocytic cells adhesion to
endothelial cells [41].
Magnolol prevents platelet aggregation and thrombus
formation
The anti-platelet effect of magnolol and honokiol
has been known for more than 20 years. Teng et al.
firstly reported that magnolol and honokiol inhibitedr system
ect Reference
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calcium mobilization in platelets caused by collagen,
arachidonic acid or thrombin [42]. Besides, collagen-
induced platelet serotonin release was also inhibited by
magnolol (3–30 μM) [43]. Using TCA method to meas-
ure the radioactive product and albumin in rat spleen
microsomes or membrane fractions of human PMNs,
magnolol and honokiol significantly inhibited the activity
of acetyl-CoA: 1-alkyl-sn-glycero-3-phosphocholine acet-
yltransferase, a key enzyme in the biosynthesis of
platelet-activating factor (IC50 60–150 μM) [44].
Pharmacodynamics, Pharmacokinetics and Safety Test of
Magnolol
The pharmacokinetics of magnolol are linear in vivo be-
cause that there were no significant difference in elimin-
ation half-life and total body clearance between
intravenous injection and intravenous infusion [45]. The
linear pharmacokinetics was found from a dose of 2 to
10 mg/kg via intravenous injection [46]. After rectal ad-
ministration of magnolol (24.4 mg/kg) and honokiol
(13.5 mg/kg), respectively, the linear concentration-time
profiles of magnolol (from 40 to 400 ng/ml) and hono-
kiol (from 20 to 200 ng/ml) in rat plasma could also be
detected using a HPLC method [47]. However, LC/MS
offered a larger range of linear concentration-time pro-
files of both magnolol and honokiol from 3.13 to
800 ng/ml [48].
In experimental studies, intravenous injection of mag-
nolol at the dosage of 2–10 mg/kg revealed the Cmax
around 10 μg/ml (40 μM), while the Cmax of 20 mg/kg
magnolol via oral administration was 0.1 μg/ml
(0.4 μM). The oral bioavailability of magnolol was
around 4–5% [49,50]. The elimination half-life of mag-
nolol was around 15 minutes and total body clearance
was 72–75 ml/min/kg [50,51]. Tissue distribution of
magnolol was predominantly in the liver, kidney, brain,
lung, and heart after oral administration [50]. In healthy
human subject, oral administration of magnolol could
retain in plasma for more than 1 hour [51].
The safety test of magnolol or extracts of Magnolia
bark has been reported. In pre-clinical study, oral ad-
ministration (mice: 0.625-2.5 g/kg; rat: 0.06-0.48 g/kg/
day for 21 days or 0.06-0.24 g/kg/day for 90 days) of
ethanol extracts (94% magnolol and 1.5% honokiol) of
Magnolia bark neither induced drug-related side effects
nor altered immune response [52,53]. However, oral ad-
ministration of 5–10 g/kg of Magnolia bark extracts for
14 days decreased liver and renal function in rat [54].
Daily oral intake 7.5 g of Hangekobokuto (containing 3 g
Magnolia cortex per 17 g of Hangekobokuto) before
meal for 2 weeks did not change the gastrointestinal
symptom rating scale for healthy group and improved
gastrointestinal symptoms in patients with functionaldyspepsia [55]. A randomized, double-blind, placebo-
controlled clinical study showed that oral administration
of capsuled extracts of Magnolia officinalis and Phello-
dendron amurense (250 mg, three times a day for
6 weeks) was well tolerated in both healthy and obese
patients, and regulation of cortisol only in obese patients
was a benefit for weight control [56].
Summary
Neutrophil infiltration, change of microRNA regulation,
and activation of innate immunity and subsequent pro-
inflammatory cytokine releasing as well as increasing
oxidative stress in response to myocardial ischemic/
reperfusion injury lead to cardiac arrhythmia and myo-
cardial contractile dysfunction [57-59]. Endothelial dam-
age triggers inflammation reaction and atherosclerotic
change, platelet aggregation and thrombus formation,
while mediators released by inflammatory cells promote
vascular smooth muscle cell proliferation, all of which
result in vascular occlusion [60-62]. The cardiovascular
protections of magnolol result from attenuating ische-
mic/reperfusion heart injury, reducing atherosclerotic
change and endothelial cell apoptosis, inhibiting neutro-
phil activation/adhesion and vascular smooth muscle cell
proliferation, preventing platelet aggregation and throm-
bosis, and promoting vessel relaxation (Figure 2), and
such cardiovascular protection effects regulated by mag-
nolol are cell type specific and dose-related. In this
article, we define that magnolol concentration at 10-7-
10-4 mg/kg in vivo or ≦ 1 μM in vitro acts as a low dos-
age, 10-4-10-2 mg/kg in vivo or 1–100 μM in vitro is the
moderate dosage, while ≧10-1 mg/kg in vivo or
≧100 μM in vitro will be the high dosage (Tab 1 and 2).
In general, lipid peroxidation inhibition ability of mag-
nolol is linear, dose-dependent in physiologically low
and moderate dosages. Under low dosage, anti-oxidation
capacity of magnolol results in preventing myocardial
infarction-induced ventricular arrhythmia and reducing
infarct area. Under moderate dosage, the lipid peroxida-
tion inhibition by magnolol protects myocardium from
ischemic/reperfusion injury and neutrophil infiltration,
attenuates postangioplastic restenosis and atheroscler-
otic change. Moderate concentration of magnolol also
reduces vascular endothelial cell apoptosis via inhibiting
NF-κB signaling pathway. Besides, the anti-inflammation
ability of magnolol is promising under moderate concen-
tration resulting in abrogating neutrophil Mac-1
mediated adhesion ligand expression, PKC-associated
migration, macrophage activation and neutrophil-
endothelial adhesion by reduction of VACM-1 and
ICAM-1 expression via inhibiting NF-κB and STAT3
signaling pathway, respectively.
Moderate to high concentration of magnolol acts on
vascular smooth muscle cells. Moderate concentration
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and high dosage further inhibit vascular smooth muscle
cell proliferation through decreasing ERK1/2 activity. In
addition, inhibition of platelet activation, aggregation as
well as thrombus formation by magnolol are observed
under the moderate to high concentration. It is worth to
notify that only a high dosage of magnolol can release
smooth muscle tone and subsequently lead to vasodilata-
tion via regulation of Ca2+ channel. All the cell type
specific and dose-related effects of magnolol on cardio-
vascular protection have been summarized in Tables 1
and 2.
Conclusion
Multifunction of magnolol on cardiovascular system
suggests the great potential of such a traditional Chinese
medicine in treating or preventing cardiovascular dis-
eases. From the clinical point of view, all the cardiovas-
cular protection in vivo by magnolol can be observed
under or below the dosage of 0.1 mg/kg via intravenous
injection according to those above research achieve-
ments. To reach the therapeutic level through oral ad-
ministration with 5% of oral bioavailability, 2 mg/kg per
day, i.e. daily 120 mg of magnolol for a 60-kg adult, may
be sufficient for cardiovascular protection, and such a
dosage is applicable. We conclude that magnolol is a
non-steroid and non-aspirin compound with strong car-
diovascular protection ability, which has a great poten-
tial of preventing cardiovascular insults under daily
intake in high-risk patients. Further clinical trials for in-
vestigation of safety and therapeutic range of magnolol
in a healthy and a high-risk group should be warranted.
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